Intellia Therapeutics, Inc. (NTLA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 10M 20M 30M Q1 '17: 6.2M Q2 '17: 5.9M Q3 '17: 7.3M Q4 '17: 6.7M Q1 '18: 7.5M Q2 '18: 7.7M Q3 '18: 7.4M Q4 '18: 7.9M Q1 '19: 10.4M Q2 '19: 11.1M Q3 '19: 10.6M Q4 '19: 10.9M Q1 '20: 12.9M Q2 '20: 16.3M Q3 '20: 22.2M Q4 '20: 6.6M Q1 '21: 6.4M Q2 '21: 6.5M Q3 '21: 7.2M Q4 '21: 12.9M Q1 '22: 11.3M Q2 '22: 14M Q3 '22: 13.3M Q4 '22: 13.6M Q1 '23: 12.6M Q2 '23: 13.6M Q3 '23: 12M Q4 '23: 0 Q1 '24: 28.9M Q2 '24: 7M Q3 '24: 9.1M Q4 '24: 12.9M Q1 '25: 16.6M Q2 '25: 14.2M Q3 '25: 13.8M Q4 '25: 23M Q1 '26: 15M Q2 '26: 7.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

0 4M 8M 12M Q3 '18: 7.4M Q4 '18: 7.9M Q1 '19: 10.4M Q2 '19: 11.1M Q3 '19: 10.6M Q4 '19: 10.9M Q3 '18 Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '16: -7.7M Q4 '16: -10.8M Q1 '17: -12.9M Q2 '17: -16M Q3 '17: -15.9M Q4 '17: -24.7M Q1 '18: -22.4M Q2 '18: -23.6M Q3 '18: -24.1M Q4 '18: -20.7M Q1 '19: -23.8M Q2 '19: -27.5M Q3 '19: -25.3M Q4 '19: -29.8M Q1 '20: -33M Q2 '20: -33M Q3 '20: -28.1M Q4 '20: -42.4M Q1 '21: -46.4M Q2 '21: -69M Q3 '21: -72M Q4 '21: -80.4M Q1 '22: -144.2M Q2 '22: -98.3M Q3 '22: -105.5M Q4 '22: -110.1M Q1 '23: -112M Q2 '23: -132.3M Q3 '23: -131.1M Q4 '23: -139.9M Q1 '24: -114M Q2 '24: -139M Q3 '24: -144.8M Q4 '24: -136.4M Q1 '25: -120.8M Q2 '25: -110M Q3 '25: -111.5M Q4 '25: -98.7M Q1 '26: -100.5M Q2 '26: -112.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '16: -7.5M Q4 '16: -10.6M Q1 '17: -12.6M Q2 '17: -15.6M Q3 '17: -15.4M Q4 '17: -24M Q1 '18: -21.4M Q2 '18: -22.2M Q3 '18: -22.7M Q4 '18: -19.1M Q1 '19: -21.9M Q2 '19: -25.7M Q3 '19: -23.6M Q4 '19: -28.3M Q1 '20: -31.8M Q2 '20: -32.4M Q3 '20: -27.8M Q4 '20: -42.2M Q1 '21: -46.2M Q2 '21: -68.8M Q3 '21: -71.6M Q4 '21: -81.2M Q1 '22: -146.9M Q2 '22: -100.7M Q3 '22: -113.2M Q4 '22: -113.4M Q1 '23: -103.1M Q2 '23: -123.7M Q3 '23: -122.2M Q4 '23: -132.2M Q1 '24: -107.4M Q2 '24: -147M Q3 '24: -135.7M Q4 '24: -128.9M Q1 '25: -114.3M Q2 '25: -101.3M Q3 '25: -101.3M Q4 '25: -95.8M Q1 '26: -96.2M Q2 '26: -106.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q3 '18 Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19

Operating Cash Flow Quarterly

-180M -120M -60M 0 60M 120M 180M Q3 '16: -7.6M Q4 '16: -14.4M Q1 '17: -11.4M Q2 '17: -15.7M Q3 '17: -16.9M Q4 '17: -21.3M Q1 '18: -17.8M Q2 '18: -22.5M Q3 '18: -12.5M Q4 '18: -8.5M Q1 '19: -21.5M Q2 '19: -27.7M Q3 '19: -25.4M Q4 '19: -28.7M Q1 '20: -38.5M Q2 '20: 57.4M Q3 '20: -28.6M Q4 '20: -40.2M Q1 '21: -52.4M Q2 '21: -53M Q3 '21: -65M Q4 '21: -54.7M Q1 '22: -79.8M Q2 '22: -85.1M Q3 '22: -78.5M Q4 '22: -89.9M Q1 '23: -109.3M Q2 '23: -90.3M Q3 '23: -101.4M Q4 '23: -93.1M Q1 '24: -120.7M Q2 '24: -58.2M Q3 '24: -84.8M Q4 '24: -85.2M Q1 '25: -148.9M Q2 '25: -99.6M Q3 '25: -76.9M Q4 '25: -69.3M Q1 '26: -117.3M Q2 '26: -83.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-180M -120M -60M 0 60M 120M 180M Q3 '16: -8.2M Q4 '16: -17.8M Q1 '17: -15.6M Q2 '17: -16.9M Q3 '17: -19.2M Q4 '17: -23.7M Q1 '18: -19.6M Q2 '18: -23.4M Q3 '18: -14.5M Q4 '18: -10.1M Q1 '19: -23M Q2 '19: -28.6M Q3 '19: -27.2M Q4 '19: -31.2M Q1 '20: -39.4M Q2 '20: 56.4M Q3 '20: -29.3M Q4 '20: -41.2M Q1 '21: -54.8M Q2 '21: -55.9M Q3 '21: -69.6M Q4 '21: -57.5M Q1 '22: -81.2M Q2 '22: -89.1M Q3 '22: -82.8M Q4 '22: -93.8M Q1 '23: -113.2M Q2 '23: -94.6M Q3 '23: -105.7M Q4 '23: -94.6M Q1 '24: -123.2M Q2 '24: -59.2M Q3 '24: -86.1M Q4 '24: -86.2M Q1 '25: -149.7M Q2 '25: -99.9M Q3 '25: -76.9M Q4 '25: -69.4M Q1 '26: -117.4M Q2 '26: -84.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '21: 68.2M Q3 '21: 73.7M Q1 '22: 74.8M Q2 '22: 75.8M Q3 '22: 76M Q1 '23: 87.8M Q2 '23: 88.2M Q3 '23: 88.6M Q1 '24: 95.5M Q2 '24: 97M Q3 '24: 101M Q1 '25: 103.5M Q2 '25: 103.7M Q3 '25: 110.2M Q1 '26: 118.5M Q2 '26: 133.5M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-21.00 -14.00 -7.00 0.00 7.00 14.00 21.00 Q3 '16: -20.04 Q4 '16: -10.78 Q1 '17: -1.25 Q2 '17: -1.34 Q3 '17: -1.56 Q4 '17: -1.86 Q1 '18: -2.01 Q2 '18: -2.08 Q3 '18: -2.17 Q4 '18: -1.99 Q1 '19: -1.97 Q2 '19: -2.01 Q3 '19: -1.97 Q4 '19: -2.11 Q1 '20: -2.25 Q2 '20: -2.30 Q3 '20: -2.28 Q4 '20: -2.40 Q1 '21: -2.46 Q2 '21: -2.86 Q3 '21: -3.36 Q4 '21: -3.77 Q1 '22: -5.04 Q2 '22: -5.36 Q3 '22: -5.88 Q4 '22: -6.16 Q1 '23: -5.37 Q2 '23: -5.44 Q3 '23: -5.33 Q4 '23: -5.41 Q1 '24: -5.36 Q2 '24: -5.48 Q3 '24: -5.44 Q4 '24: -5.24 Q1 '25: -5.22 Q2 '25: -4.68 Q3 '25: -4.26 Q4 '25: -3.82 Q1 '26: -3.53 Q2 '26: -3.35 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.